In Middle East and North Africa (MENA) countries, the business environment remains unsettled due to rapid changes in governments which would create of new business opportunities. The pharmaceutical market is one of the steadily growing markets in MENA due to the increase in the size and number of new hospitals.
Hikma Pharmaceuticals is a multinational pharmaceutical group which operates in the MENA region, the USA and Europe. Hikma started to produce and market generics in local markets in 1978 and became listed on the London stock exchange in 2005, reaching over US$1 billion turnover after three decades and having presence in more than 50 markets. The massive growth of this global company initiated via high investments and successful strategies in different market entries.
The globalisation strategy has enabled Hikma to penetrate many markets and to become a globally recognised pharmaceutical company. This case presents a globally recognised company from MENA as an Emerging Markets Multinational.
Restricted to Registered users only
Download (533kB)